{
  "ticker": "LLY",
  "target_date": "2025-09-24",
  "actual_date": "2025-09-24",
  "collected_at": "2025-12-08T12:19:15.182519",
  "price": {
    "open": 744.9,
    "high": 745.84,
    "low": 735.08,
    "close": 740.7620849609375,
    "volume": 2243000,
    "change_1d_pct": -0.69,
    "change_7d_pct": -0.85,
    "change_30d_pct": 16.27
  },
  "technicals": {
    "rsi_14": 49.49,
    "sma_20": 745.36,
    "sma_50": 735.6,
    "macd": 6.342,
    "macd_signal": 6.758,
    "macd_histogram": -0.416,
    "bb_upper": 767.7,
    "bb_lower": 723.02,
    "price_vs_sma20_pct": -0.62,
    "price_vs_sma50_pct": 0.7,
    "volume_ratio": 0.69
  },
  "fundamentals": {
    "market_cap": 892449652736,
    "pe_ratio": 48.77658,
    "forward_pe": 43.933365,
    "price_to_book": 37.482307,
    "price_to_sales": 15.019399,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.47,
    "pct_from_52w_low": 59.6
  },
  "macro": {
    "spy": {
      "price": 661.1,
      "change_1d_pct": -0.32,
      "change_7d_pct": 0.44
    },
    "vix": {
      "level": 16.18,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.15
    },
    "dollar_index": {
      "level": 97.87
    },
    "gold": {
      "price": 3732.1
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?",
      "source": "Yahoo",
      "datetime": 1758746678,
      "summary": "Once up and running, it and other projects should make the company's supply chain stronger.",
      "url": "https://finnhub.io/api/news?id=8cf6386dfee6bed163a4014ccea9ca11991ef169a385ea7819f2cea7023e1f7f"
    },
    {
      "headline": "Podcast: How oral GLP-1RAs are set to impact the obesity market",
      "source": "Yahoo",
      "datetime": 1758735806,
      "summary": "As Eli Lilly and Novo Nordisk await approval of their oral GLP-1RAs, the healthcare editorial team discuss data and market opportunity.",
      "url": "https://finnhub.io/api/news?id=9afa70e828c131f3f4f9f69966c58ab74c940a851bd8641457a95baa571f12ef"
    },
    {
      "headline": "LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?",
      "source": "Yahoo",
      "datetime": 1758731100,
      "summary": "Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.",
      "url": "https://finnhub.io/api/news?id=07331e108658c7db68779258eaf6906b842da0469b7e09acd3da1b6bc104f606"
    },
    {
      "headline": "Lilly to build $6.5B Houston factory for its first obesity pill",
      "source": "Yahoo",
      "datetime": 1758715980,
      "summary": "The pharmaceutical giant\u2019s expansion into Texas will create 615 full-time jobs and receive $5.5 million in state funding.",
      "url": "https://finnhub.io/api/news?id=ec89b5bde8fd06d2cdcebbd344f3c774fe25daf187eb7dde6d8c2595ede3ee1d"
    },
    {
      "headline": "Eli Lilly to build $6.5bn orforglipron production site in Texas",
      "source": "Yahoo",
      "datetime": 1758714048,
      "summary": "The API facility is part of Eli Lilly\u2019s $27bn US manufacturing drive.",
      "url": "https://finnhub.io/api/news?id=ffe4249466168ff87aeba6c5a010eb611b325973c3013a48fef93014695ef56e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-22",
      "description": "xslF345X05/form4-09222025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000009/xslF345X05/form4-09222025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-19",
      "description": "xslF345X05/form4-09192025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000007/xslF345X05/form4-09192025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142191.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000126238825000004/xslF345X05/wk-form4_1758142191.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142140.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000242/xslF345X05/wk-form4_1758142140.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142082.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000134082325000006/xslF345X05/wk-form4_1758142082.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}